CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Peloton Therapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Peloton Therapeutics Inc
2330 Inwood Rd Ste 226
Phone: (972) 629-4100p:972 629-4100 Dallas, TX  75235-7323  United States Fax: (302) 655-5049f:302 655-5049
On 7/10/2019, the Company filed a Registration Withdrawal Request of its Form S-1 (File No. 333-231077) with the SEC, initially filed with the Commission on April 26, 2019. The Company is seeking withdrawal of the Registration Statement because the Company has entered into the Agreement and Plan of Merger, dated May 20, 2019, by and among the Company, Merck Sharp & Dohme Corp. and Palm Merger Sub, Inc.
Business Summary
Peloton Therapeutics, Inc. is a clinical stage pharmaceutical company. The Company is focused on developing medicines for patients with cancer and other conditions. The Company's product pipeline includes Hypoxia-inducible factor-2a (HIF-2a). HIF-2a is a transcription factor that, in part, regulates the body’s response to diminished availability of oxygen. The Company’s lead drug candidate, PT2977, is an oral HIF-2a. The Company is focused on developing PT2977 for the treatment of kidney cancer, specifically metastatic clear cell renal cell carcinoma (mRCC) and von Hippel-Lindau (VHL) disease-associated renal cell carcinoma (RCC). HIF-2a is aberrantly activated in these diseases as a result of the inactivity of the VHL tumor suppressor. The Company is also developing PT2567, an oral HIF-2a inhibitor, for non-oncology indications.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/201912/31/2018YesYes---

Industries
SIC Code Description
8731 Commercial physical and biological research
2836 Biological products, except diagnostic substances

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board David V.Goeddel 68
Chief Executive Officer, Director John A.Josey 8/1/2013 8/1/2011
Chief Scientific Officer Eli M.Wallace 1/1/2015 1/1/2011
3 additional Officers and Directors records available in full report.

General Information
Number of Employees: 64 (As of 3/31/2019)
Outstanding Shares: 44,461,361 (As of 3/31/2019)
Stock Exchange: NASD
Federal Tax Id: 273349428
Fax Number: (302) 655-5049


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023